Onapristone
- Generic Name
- Onapristone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39NO3
- CAS Number
- 96346-61-1
- Unique Ingredient Identifier
- H6H7G23O3N
- Background
Onapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy.
- Associated Conditions
- -
- Associated Therapies
- -
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Phase 2
Active, not recruiting
- Conditions
- Refractory Endometrial AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Serous AdenocarcinomaRefractory Endometrial Mixed Cell AdenocarcinomaRefractory Endometrial Undifferentiated CarcinomaRefractory Endometrial Clear Cell AdenocarcinomaRefractory Endometrial Endometrioid Adenocarcinoma
- Interventions
- Drug: Extended-release OnapristoneDrug: AnastrozoleOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDiagnostic Test: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)Diagnostic Test: Progesterone Receptor Positive ( PGR Positive; PR Positive)
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 14
- Registration Number
- NCT04719273
- Locations
- 🇺🇸
Jefferson Abington Hospital, Abington, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath